Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources


May 19, 2025

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically

American Thoracic Society (ATS) 2025
Read More
May 17, 2025

Revolutionizing Immunology: Oral Medicines with Biologics-like Activity

American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
October 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More
September 25, 2024

Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo

European Academy of Dermatology and Venereology (EADV) 2024
Read More
May 22, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Model of Asthma

American Thoracic Society (ATS) 2024
Read More
May 21, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation In Vivo in a Mouse Model

Digestive Disease Week (DDW) 2024
Read More
March 8, 2024

Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis

American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More